Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa

Dermatol Ther. 2020 Aug 23;e14205. doi: 10.1111/dth.14205. Online ahead of print.

Abstract

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of follicular epithelium; many comorbidities occur that disrupt the quality of life of patients. Amyloidosis is one of them. We present a case with systemic amyloidosis secondary to HS and responding positively to secukinumab therapy. Secukinumab may also be an important option for amyloidosis findings in HS patients.

Keywords: amyloidosis; hidradenitis suppurativa; secukinumab.